Summary:
Click image to enlarge
Bioluminux Clinical Research in Naperville is now actively recruiting participants for a clinical trial investigating a new GLP-1 drug given once weekly by injection for individuals living with obesity or overweight; the study lasts 38 weeks with an additional 4-week follow-up, and participants have a 4 in 5 chance of receiving the investigational study drug (only 1 in 5 will receive placebo), with total compensation of up to $2800 for time and travel.
Criteria:Adults aged 18–75 years
BMI between 27–50 kg/m²
Diagnosed with Type 2 Diabetes for at least 3 months
Latest HbA1C value between 7.0% (53.0 mmol/mol) and 10.5% (91.3 mmol/mol)
Not currently using insulin or GLP-1 medications (e.g., Ozempic, Mounjaro)
Blood pressure below 160/95 mmHg
No history of stroke, heart disease, or Type 1 diabetes
Can be on other medications (e.g., Metformin), except insulin or GLP-1 drugs
A urine drug of abuse screening test will be done at screening
Qualified Participants May Receive:
- Study-related care and monitoring
- Regular health assessments
- The investigational medication or placebo at no cost ( a 4 in 5 chance of receiving the investigational study drug)
- Compensation for time and travel up to $2800